In our previous study, CD44highCD24low breast CSCs exhibited high levels of NRF2 signaling, and NRF2-silencing led to retarded tumor growth, suppression of sphere formation and invasion capacity, and anticancer sensitization (36). The gene discussed is NFE2L2; the disease is neoplasm.